Background: Breast reduction has traditionally been performed under general anesthesia with adjunct opioid use. However, opioids are associated with a wide variety of adverse effects, including nausea, vomiting, constipation, postoperative sedation, dizziness, and addiction. Objectives: This study compares bilateral breast reduction using a multimodal opioid-free pain management regimen vs traditional general anesthesia with adjunct opioids.
and addiction. 2 Opioids also carry significant morbidity, prolong hospital stays, increase use of medications needed to reverse its side effects, and decrease patient satisfaction overall. 3, 4 Although there has been an evolution towards decreasing the use of opioids in surgical patients, there are no studies in which patients undergoing breast reduction completely forewent the use of opioids in preoperative, intraoperative, and postoperative settings. Valente et al showed a significant reduction in postoperative opioid use in breast reduction patients who received preemptive local anesthetic injection prior to incision, however, patients still underwent general anesthesia with adjunctive use of opioids. 5 The purpose of our study is to evaluate relative patient outcomes for those undergoing breast reduction surgery via a multimodal opioid-free pain management regimen vs the traditional approach of general anesthesia with adjunct opioid use.
METHODS
This study was approved by the Queen's Medical Center Institutional Review Board and adhered to the guidelines of the Declaration of Helsinki. All patients provided written informed consent.
Between February 2004 and January 2017, the senior plastic surgeon (F.D.P.) performed bilateral breast reductions on 83 female patients. In 2009, motivated by concern regarding the adverse side effects frequently encountered by patients using opioids, the senior plastic surgeon switched from the traditional approach of utilizing general anesthesia and adjunct opioids to an opioid-free multimodal pain management regimen. Data prior to 2009 were collected in a retrospective manner and data after 2009 were collected prospectively. No patients were excluded from the study determined by specific inclusion and exclusion criteria.
Inclusion criteria consisted of a diagnosis of bilateral breast hypertrophy, planned outpatient surgery, American Society of Anesthesiologists (ASA) Physical Classification of l or 2 (absence of severe systemic disease), 6 removal of over 500 grams of tissue per breast, and medical clearance by a primary care physician. Exclusion criteria included individuals with an allergy to opioids, celecoxib, gabapentin, acetaminophen, or local anesthetics, and patients with a history of alcoholism, drug addiction, or depression requiring pharmacologic treatment. Data from both retrospective and prospective aspects of the study were subjected to identical inclusion and exclusion criteria.
Group 1 included 39 patients from 2004 to 2009 who underwent breast reduction under general anesthesia with adjunct use of opioids (fentanyl or morphine). Local anesthetic used in this group consisted of 1% lidocaine with 1:100,000 epinephrine in areas to be de-epithelialized. All patients in group 1 were prescribed opioid analgesics for postoperative pain control as needed, with 31 patients given hydrocodone with acetaminophen, and 4 patients given oxycodone with acetaminophen. Groups 2 and 3 included 44 patients who underwent surgery without the use of preoperative or intraoperative opioids. In group 2, twenty-six patients underwent surgery with intravenous sedation combined with local anesthesia. In group 3, eighteen patients underwent surgery with general anesthesia. Patients in both groups 2 and 3 had multimodal anesthesia care (MAC) via an opioid-free regimen, which included preoperative administration of 400 mg of celecoxib and 1200 mg of gabapentin 30 to 60 minutes prior to incision, and local regional infiltration with 0.25% lidocaine with 1:400,000 epinephrine prior to incision and during surgery. Before wound closure, breasts were infiltrated with 3 mg/kg of 0.25% bupivacaine with 1:200,000 epinephrine. Oral acetaminophen 1000 mg every 6 hours was prescribed for postoperative pain control as needed for patients in groups 2 and 3. All patients in the 3 groups received preemptive antiemetic therapy prior to leaving the operating room.
Age, medical history, social history, body mass index, breast skin and vascular patterns, the amount of breast liposuction, volume of breast tissue resected and the amount of local anesthetic injected in mg/kg were recorded (Table 1) . Outcome variables included duration of surgery, time from end of operation to discharge, opioid and antiemetic use in the Post-Anesthesia Care Unit (PACU), and unplanned postoperative hospital admissions. Duration of surgery was measured from the time of incision to application of dressings. Criteria used to determine if the patient was ready for discharge included vital signs within normal limits, ability to stand erect without dizziness or lightheadedness, well-controlled pain, and ability to urinate. While in the PACU, postoperative nausea, vomiting, and pain were qualitatively determined by whether or not patients required opioids or antiemetics for pain not adequately controlled or for uncontrolled nausea and vomiting, respectively. Patients with nausea alone or nausea with retching of short duration not requiring antiemetics were not reported.
Following discharge, all patients in this study were seen at least once during the first 14 days after surgery, with a majority seen within 2 to 7 days. In addition, a few patients also contacted the senior plastic surgeon's office by phone if they had concerns prior to their follow-up visits. Postdischarge outcome and complication variables included nausea and vomiting requiring antiemetics, pain requiring opioids, hematoma/seroma formation, fat necrosis, wound dehiscence, cellulitis, and the need to return to the operating room within 30 days following discharge.
Statistical analyses were conducted using the Fisher's exact test with mid-p, two-sided values of P < 0.05 considered significant. The authors have no conflicts of interest to disclose.
RESULTS
Patient demographics were not statistically different between the three groups regarding average age (37 years old), age range (18-56 years), smoking history, body mass index, breast skin and vascular patterns, percent who underwent concomitant breast liposuction, or the average volume of breast tissue resected (Table 1) . Table 2 shows differences between group 1 patients that received adjunct opioids and groups 2 and 3 that had opioid-free procedures. The results were statistically significant regarding duration of surgery (P < 0.05), time from end of the operation to discharge (P < 0.05), unplanned postoperative hospital admissions (P < 0.05), and opioid use in the PACU (P < 0.001). The results support forgoing the use of pre-, intra-, and postoperative opioids for bilateral breast reduction in all measured outcome variables, except for the duration of surgery ( Table 2) .
None of the patients who underwent intravenous sedation in group 2 required antiemetic medication in the PACU as compared to Group 1 (P < 0.05). Five patients (12.8%) from group 1 required unplanned admission to the hospital for either uncontrolled pain or nausea and vomiting (P < 0.05).
Tables 2 and 3 also show differences amongst the 2 types of opioid-free procedures. Statistically significant differences supporting the use of intravenous (IV) sedation included shorter time from end of operation to discharge (P < 0.05), fewer patients who required opioid use in the PACU (P < 0.05), and fewer patients who required antiemetic use in the PACU (P < 0.05). A statistically significant difference supporting the use of an opioid-free procedure utilizing general anesthesia included shorter duration of surgery (P < 0.05). An outcome variable that showed no statistically significant difference between groups 2 and 3 was the number of patients who required unplanned postoperative hospital admissions, which was none for both groups.
Outcomes and complications encountered by patients following discharge are shown in Table 4 . Two patients in group 3 (11.1%) called the evening following discharge with complaints that acetaminophen was not alleviating their pain, and were prescribed an opioid analgesic. All patients in group 1 reported use of prescribed opioid analgesics for at least 48 hours after discharge, which was a statistically significant difference in opioid requirement during this time period between group 1 and group 2 (P < 0.001), and group 1 and group 3 (P < 0.005). Furthermore, 7 patients in group 1 (18%) stopped taking opioid analgesics after 48 hours and switched to acetaminophen, 24 patients (61.5%) stopped between 48 hours and 5 days with a subsequent switch to acetaminophen, and 8 patients (20.5%) continued taking opioid analgesics after 5 days. In group 3, the two patients (11.1%) who required opioid analgesics switched back to acetaminophen after 48 hours. Patient requirement of antiemetics following discharge was another statistically significant difference seen between group 1 and group 2 (P < 0.05) and group 1 and group 3 (P < 0.05), with more patients in group 1 requiring antiemetics following discharge. There were no other statistically significant differences amongst the 3 groups in regards to outcomes or complications experienced after discharge. One patient in group 1 (2.6%) experienced minor fat necrosis that required outpatient management. Three patients in group 1 (2.6%), two patients in group 2 (7.7%), and one patient in group 3 (5.5%) presented with partial wound dehiscence postdischarge that only required conservative treatment with silver sulfadiazine cream. One patient in group 1 (2.6%) and one patient in group 2 (3.8%) experienced cellulitis following discharge that resolved within 2 weeks with the use of oral antibiotics.
DISCUSSION
Breast reduction traditionally entails general anesthesia with adjunct opioid administration. It is well documented that opioid analgesics have numerous adverse side effects including nausea, vomiting, excessive sedation, clouded sensorium, constipation, dizziness, respiratory depression, and addiction. 2 Opioids may also cause paradoxical hyperalgesia due to opioid-induced neural plasticity. This appears to affect both the central and peripheral nervous systems, and may lead to sensitization of the pain pathways. 7 Studies have also shown that opioid administration halts the production of beta-endorphins and impairs the function of mu-opioid receptors. [8] [9] [10] [11] Beta-endorphins have been proposed to be 18 to 33 times more potent analgesics than morphine. 12 Therefore, the administration of opioid analgesics appears to actually impair the body's innate pain response mechanism. Under general anesthesia, pain stimuli still reach the brain. 13 This results in 2 oppositional concepts regarding endorphin production and utilization. Endorphin release is believed to enhance in response to a stressor, such as sharp pain. 14 However, if present in adequate amounts, as when opioids are not used, endorphins are also quickly utilized to control the pain. By providing preemptive gabapentin, celecoxib, and local anesthetic, the intraoperative conduction of pain to the brain is significantly reduced but endorphin release is preserved resulting in adequate pain control after surgery. We postulate that this phenomenon explains why patients in our study who underwent opioid-free surgery experienced mild pain that was alleviated with acetaminophen alone in all group 2 patients and in 83.3% of group 3 patients. Another benefit of forgoing opioid use is that endorphins enhance individuals' moods. 8, 9, 15, 16 We are currently conducting a study regarding this observation and our preliminary results indicate a sense of well-being rather than a depressive state when opioids are not utilized. In order to avoid adverse effects of opioids, this study incorporated the use of multimodal anesthesia care (MAC) consisting of preoperative and intraoperative opioid-free regimens for patients undergoing bilateral breast reduction. Previous studies have demonstrated that the administration of cyclooxygenase-2 inhibitors and gabapentin in the preoperative setting significantly reduces postoperative pain. 2, 17 Administration of these medications combined with preincisional, intraoperative, and preclosure injection of local anesthetics allowed for adequate postoperative pain control with acetaminophen (group 2) and with opioid use in only 16.7% of patients operated under general anesthesia (group 3). This difference may be explained by inadequacy of local anesthetic infiltration when general anesthesia is utilized since no feedback from the patient is present. The difference in PACU opioid use between group 1, who received adjunct opioids, and groups 2 and 3, who did not receive adjunct opioids, is highly significant (P < 0.001) ( Table 2) . Following discharge, this difference in opioid use remained statistically significant between group 1 and groups 2 and 3 as seen in Table 4 . Opioid-free breast reduction also significantly reduced the need for antiemetics in the PACU and postdischarge, decreased the time from the end of surgery to discharge, and decreased the number of unplanned postoperative hospital admissions.
Of the measured variables, only the duration of surgery was adversely affected by forgoing the use of opioids due primarily to the additional time required for local anesthetic infiltration. This is well offset by the other measured variables such as the drastically decreased use of postoperative opioid analgesics (P < 0.001), the decrease in average time from the end of operation to discharge (P < 0.05), and the decrease in unplanned hospital admissions (P < 0.05) ( Table 2 ).
In our study, when general anesthesia was used in group 3, adherence to the recommended standard dose of 7 mg/kg of lidocaine with epinephrine was simple since the exact volume of solution was made available for intraoperative infiltration. The same was true for bupivacaine with epinephrine that was infiltrated at the completion of the procedures both in groups 2 and 3 in the recommended dosage of 3 mg/kg. However, when intravenous sedation was utilized in group 2, we found that 7 patients, or 26.9% of group 2 patients, required an average of 7.6 mg/kg in order to keep them comfortable during the procedure (Table 1) . Although higher dosages above the manufacturer recommended maximum dosage were required in certain patients, all were made aware of publications that had reported the safety of lidocaine with epinephrine infiltration above 7 mg/kg into subcutaneous tissue.
Traditionally, 4 mg/kg of lidocaine without epinephrine and 7 mg/kg of lidocaine with epinephrine has been suggested by the manufacturers as the maximal safe dose for soft tissue injection. [18] [19] [20] Unfortunately, no data exist regarding how this maximum safe dosage was ascertained 19, 21 and no prospective randomized trial has been done as this may cause patient harm. However, it is well documented that toxicity of lidocaine manifests itself at serum levels above 5 mcg/mL. 22 Although an optimal prospective study would be in humans, a study by Mottura and Procickieviez utilizing porcine models studied the effects of purposefully infiltrating subcutaneous tissue of the abdomen with double the manufacturer's recommended maximum safe dosage of lidocaine with epinephrine, or 14 mg/kg, and subsequent subjection of these pigs to abdominoplasty. A total of 7 samples of plasma lidocaine levels were obtained from each pig at 15 minute intervals during the operation, with every serum level having remained under the critical limit of 5 mcg/mL. 23 Although the porcine metabolism bears close resemblance to that of human beings, we do not believe that abdominoplasty in a porcine model exactly mimics the effects that this dosage of lidocaine may have during breast reduction in humans. However, this is the closest prospective study involving infiltration of significantly larger than safe dosages of lidocaine with epinephrine without having to subject humans to such a study. It must also be kept in mind that this study by Mottura and Procickieviez utilized 14 mg/kg of lidocaine with epinephrine, a dosage drastically greater than any that was infiltrated during our currently discussed breast reduction study. Other studies have also shown that absorption pharmacokinetics of dilute lidocaine injected into soft and fatty tissues differ compared with that of dermally infiltrated or intravenously injected 1% or 2% lidocaine preparations, allowing for higher maximum safe doses of lidocaine when injected into soft tissues. 21, 24 In humans, the safe infiltration of lidocaine with epinephrine into soft tissues above 7 mg/kg has been previously reported. [25] [26] [27] [28] [29] Although doses in mg/kg were not commonly listed by authors, approximation utilizing average healthy weight of a woman being 57 kg provides an estimate of maximum doses. In Zukowski et al's clinical study of breast reduction under intravenous sedation and local anesthesia, approximate doses of lidocaine infiltration up to 10.5 mg/kg with epinephrine were utilized without reported toxicity. 25 Similarly, Mottura used lidocaine infiltration in 15 cases of abdominoplasty at a dosage of approximately 8.8 mg/kg with epinephrine without noted toxicity. Intraoperative serum lidocaine levels obtained every 15 minutes in Mottura's study showed a maximum plasma concentration of 1.26 mcg/mL. 26 The same author reported 94 breast reductions, 18 mastopexies, and 56 breast augmentations without any toxic side effects related to local anesthetics utilizing the same local anesthetic dose. 27 Han et al reported absence of toxicity or toxic serum levels of lidocaine when approximately 10.5 mg/kg with epinephrine was utilized for brachial plexus blocks. Serum concentrations at 5, 15, and 30 minutes during the procedure in Han et al's study showed that the highest average value of 2.66 mcg/mL occurred at 15 minutes after lidocaine infiltration. 28 Similarly, Guth et al measured serum lidocaine concentrations following subcutaneous infiltration of the groin and showed nontoxic plasma levels at maximum doses of approximately 8.8 mg/kg. 29 Additionally, all of the patients participating in our study received midazolam as a component of their sedation. Studies have shown that benzodiazepines are capable of increasing the threshold for toxicity, specifically in regards to neurotoxicity, of local anesthetics. 30, 31 There are several limitations regarding this study. One is that group 1 consisted of a retrospective cohort while groups 2 and 3 were prospective studies. This may have resulted in unintentional inherent bias for more lenient hospital admissions in group 1 vs groups 2 and 3. To prevent this bias as much as possible, the authors adhered to objective criteria for admission, mentioned previously in the methods section. Patient bias may have also played a role in differences observed in the various outcomes between group 1 and groups 2 and 3, possibly due to the fact that prospective patients were notified of undergoing a "new" anesthesia method. However, previous studies have shown that adequate communication and patient education prior to surgery has the potential to decrease postoperative pain and opioid use when discussions include adequate explanations of endorphins and how the body naturally responds to pain, the negative effects of opioid analgesics, and mechanisms of nonopioid analgesics. This technique of preoperative patient education is ultimately beneficial to the practice of opioid-free surgery. 32 But regardless of such benefit to opioid-free surgery, in order to eliminate as much bias as possible with similar studies in the future, we recommend a double-blinded approach if possible. Another limitation is that immediate postoperative nausea, vomiting, and pain were assessed qualitatively, not quantitatively. If these criteria were recorded quantitatively, more objective data would be available for direct comparison. A third limitation is that there is relatively low power for this study. A fourth limitation and weakness of this report is that serum lidocaine levels were not measured in group 2, where an average of 7.6 mg/kg of lidocaine was infiltrated in 26.9% of patients. Although several authors have shown the safety of doses higher than 7 mg/kg of lidocaine with epinephrine ranging from 8.8 to 10.5 mg/kg in procedures similar to ours as noted above, [23] [24] [25] [26] [27] we realize that more studies based on large series of breast reductions would further ascertain a more accurate maximum dosage of lidocaine infiltration allowable. Presently, there is a surprising paucity of serum lidocaine measurements in surgery. For this reason, we strongly recommend that any breast procedures, as well as any other operations, requiring lidocaine with epinephrine infiltration over 7 mg/kg should include measurements of serum levels of lidocaine at various intervals intra-and postoperatively. Accurate documentation of the amount of lidocaine infiltrated during each operation along with its extrapolation into mg/kg is essential and best performed by the anesthesia team. The collection of this data from different centers should allow for the establishment of an improved safe dosage for lidocaine infiltration in the future. Also, future studies regarding opioid-free breast reduction may consider the comparison and efficacy of other local anesthetic options available for pain control, including liposomal bupivacaine, thoracic paravertebral nerve blocks, or pectoral nerve blocks. A final notable limitation is that no formal patient satisfaction assessment was done following the breast reduction surgeries reported in this study. Since the completion of this study, we have been conducting a separate study that specifically evaluates patient satisfaction and perceived well-being following all opioid-free surgical procedures. Although this new study will be further reported on in the future, preliminary observations thus far indicate an increase in patient satisfaction amongst those who undergo surgery without the use of opioid analgesics.
CONCLUSION
A multimodal, opioid-free approach to breast reduction is presented that utilizes preoperative gabapentin and celecoxib, preincisional and intraoperative infiltration of lidocaine with epinephrine, and bupivacaine with epinephrine infiltration just prior to wound closure. Opioid-free breast reduction, both under intravenous sedation as well as under general anesthesia, has numerous advantages that include significantly less postoperative nausea and vomiting, decreased time to discharge, and a significant reduction in unplanned postoperative hospital admissions as compared to standard breast reduction under general anesthesia with adjunct opioid use. There are particular advantages and disadvantages between the two opioid-free breast reduction techniques discussed, thus requiring the plastic surgeon to choose either approach after careful consideration of the pros and cons. For surgeons who wish to adhere to the current safe dosage of 7 mg/kg of lidocaine with epinephrine as recommended by manufacturers, opioid-free breast reduction under general anesthesia remains a superior choice. However, with future documentation of serum lidocaine levels in order to determine more accurate safe maximum dosages, IV sedation may prove equally as safe, efficient, and cost-effective.
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